Day: December 29, 2022

ROUYN-NORANDA, Quebec, Dec. 29, 2022 (GLOBE NEWSWIRE) — Chibougamau Independent Mines Inc. (CBG-TSX-V in Canada, CLL1-Frankfurt, Stuttgart and Lang & Schwarz Stock Exchanges in Germany, CMAUF-OTC in the US) is pleased to announce that it has completed its previously-announced “flow-through” private placement by issuing 2,168,966 “flow-through” shares at a price of $0.145 per share for proceeds of $314,500. Chibougamau will use the proceeds from the private placement for exploration on its properties in the Chibougamau area of Québec. At closing, Chibougamau also issued 120,000 common shares in payment of finder’s fees. Chibougamau also announces that it held a first closing of a private placement of common shares at $0.10 per share by issuing 3,450,000 shares for proceeds of $345,000. Chibougamau will use the proceeds from...

All amounts shown in this press release are in U.S. dollars unless otherwise indicated. WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) — December 29, 2022: (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that it has completed the amendments to the Company’s existing senior revolving credit facility (the “Revolver”) and its revolving UK credit facility (the “UK Facility” and collectively with the Revolver, the “Facilities”) referred to in the Company’s news release of December 23, 2022.   Details are as follows:Amendments provide relief from previous key financial covenants (Total Leverage Ratio1 (“TLR”), Minimum Adjusted EBITDA2 and Interest Coverage Ratio3 (“ICR”)) for the fourth...

New York, NY, Dec. 29, 2022 (GLOBE NEWSWIRE) — iQSTEL, Inc. (OTCQX: IQST), today released a letter to shareholders from CEO Leandro Iglesias in conjunction with announcing an annual shareholder meeting scheduled for January 31, 2023, at 11 am (EDT). The letter, included in its entirety below, discusses the company’s $105 million 2023 revenue forecast, plans to further increase profitability after posting its first profits in Q3 2022, and the latest progress toward the company’s intended Nasdaq up-listing. In advance of the annual shareholder meeting, the company has filed a Definitive Proxy Statement (https://www.sec.gov/Archives/edgar/data/1527702/000166357722000721/iqst_def14c.htm) for shareholders to elect directors and ratify the company’s independent registered public accounting firm. The Proxy also facilitates the introduction...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023 YAVNE, Israel, Dec. 29, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. “We are pleased and excited that the FDA has approved NexoBrid, an innovative, non-surgical alternative for the...

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid compared to placebo  CAMBRIDGE, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. “There is a considerable unmet need for non-surgical eschar removal for patients with severe thermal burns, and the FDA’s approval of NexoBrid marks an important...

Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) DENVER and MINNEAPOLIS, Dec. 29, 2022 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) and Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis) announce an exclusive U.S. license and distribution agreement by Nuwellis of SeaStar Medical’s Selective Cytopheretic Device (SCD) for the treatment of acute kidney injury (AKI) in children. Nuwellis will market and distribute the SCD through its direct salesforce to nephrologists and intensive care physicians who are trained in pediatric extracorporeal therapy. SeaStar Medical expects the U.S. Food and Drug Administration (FDA) to complete a substantive review of a Humanitarian Device Exemption (HDE) for the use of SCD in children (>20 kg.) with AKI during the...

The Capital Markets Authority (CMA) has licenced Admirals Kenya Limited as a non-dealing online forex trading broker under the Capital Markets Regulations. Admirals hopes the achieving of this license shall assist further growth in Africa and grant access to a stringently regulated market. Also, Admiral Markets Cyprus and Admirals South Africa jointly entered into a takeover agreement of Aglobe Investments Ltd, incorporated in the Republic of Seychelles and licensed as a securities dealer by the Seychelles Financial Services Authority.  Further information:  Kaia Gil Communication Manager of Admirals Group AS kaia.gil@admiralmarkets.com +372 53 413 764  

Banco Comercial Português, S.A. informs about Restructuring FundsAttachment2022 12 29 Fundos Reestruturação EN_vf